Fenwick & West and Goodwin Procter represented Gritstone bio, Inc. in the offering, and Cooley represented the underwriters. Gritstone bio, Inc. (Nasdaq: GRTS) announced the pricing of...
Gritstone bio’s $32.5 Million Common Stock Offering
JN BIDCO’s Acquisition of Impel Pharmaceuticals
Fenwick & West and Sidley Austin are representing Impel Pharmaceuticals Inc. in the transaction. JN BIDCO LLC announced the acquisition of Impel Pharmaceuticals Inc. (OTCQX: IMPL)....
Novartis AG’s Acquisition of Chinook Therapeutics
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
Third Harmonic Bio’s $213.1 Million IPO
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
GitLab’s $800 Million Initial Public Offering
Fenwick represented GitLab Inc. on the deal, while Latham & Watkins represented the underwriters. GitLab Inc. (Nasdaq: GTLB), provider of The DevOps Platform, announced its initial public...
Impel NeuroPharma’s $80 Million Initial Public Offering
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...